Australian regenerative medicine company Orthocell (ASX:OCC) has strengthened its North American commercial footprint, appointing a second Canadian distributor for its flagship nerve repair device Remplir, achieving full national coverage across the country's US$75 million nerve repair market. …
Orthocell expands Canadian presence with full national coverage for nerve repair device
November 5, 2025 Australian Biotech
Latest Video
New Stories
-
Todd Stephenson confirmed on ACT list for New Zealand election
September 14, 2026 - - Latest News -
Scandal-hit KPMG still holds $37 million in health department work
September 14, 2026 - - Latest News -
Canberra details tax changes with limited concessions for some innovators
September 14, 2026 - - Latest News -
The 'Dispatched' Week in Review Podcast - 11 September
September 11, 2026 - - Podcast -
Rare genetic motor neurone disease treatment finally reaches Australian patients
September 11, 2026 - - Latest News -
NSW pharmacists to deliver all childhood vaccines and treat more conditions under reforms
September 11, 2026 - - Latest News -
AI Health Summit 2026
September 10, 2026 - - Summit